Pharmacotherapeutic principles of fluid management in heart failure

References

• Benjamin Emelia J, Paul M, Alvaro A, et al. Heart disease and stroke statistics—2019 update: A report from the american heart association. Circulation. 2019 Mar 5;139(10):e56–528.
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the Impact of Heart Failure in the United States. Circ Heart Fail.. 2013 May;6(3):606–619.
   PubMed Web of Science ®Google Scholar
• Taylor CJ, Ordóñez-Mena JM, Roalfe AK et al. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study. BMJ. 2019Feb13 [cited 2020 Apr 30].364 Available from:http://www.bmj.com/content/364/bmj.l223.
   Google Scholar
• Hajar R. Congestive Heart Failure: A History. Heart Views. 2019;20(3):129–132.
   PubMedGoogle Scholar
• FIESE MJ, THAYER JM. VALUE OF SOUTHEY-LEECH TUBES IN RAPID RELIEF OF MASSIVE EDEMA. Arch Internal Med. 1950 Jan 1;85(1):132–143.
   Google Scholar
• Davis RC, Hobbs FDR, Lip GYH. History and epidemiology. BMJ. 2000 Jan 1;320(7226):39–42.
   PubMedGoogle Scholar
• Androne AS, Hryniewicz K, Hudaihed A, et al. Relation of unrecognized hypervolemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes. Am J Cardiol. 2004May15;93(10):1254–1259.
   PubMed Web of Science ®Google Scholar
• Abraham WT, Stevenson LW, Bourge RC, et al. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet. 2016 Jan 30; 387(10017):453–461.
   PubMed Web of Science ®Google Scholar
• Lala A, McNulty SE, Mentz RJ, et al. Relief and recurrence of congestion during and after hospitalization for acute heart failure: insights from DOSE-AHF and CARRESS-HF. Circ Heart Fail.. 2015 Jul;8(4):741–748. .
   PubMed Web of Science ®Google Scholar
• Ambrosy AP, Cerbin LP, Armstrong PW, et al. Body weight change during and after hospitalization for acute heart failure: Patient characteristics, markers of congestion, and outcomes – findings from ASCEND-HF. JACC Heart Fail. 2017 Jan;5(1):1–13.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure the task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (esc)developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129–2200.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Vol. 136, Circulation. Lippincott Williams and Wilkins; 2017. p. e137–61.
   Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the american college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol. 2013 Oct 15;62(16):e147–239.
   PubMed Web of Science ®Google Scholar
• Hasselblad V, Stough WG, Shah MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the escape trial. Eur J Heart Fail. 2007 Oct;9(10):1064–1069.
   PubMed Web of Science ®Google Scholar
• Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to Mortality in Advanced Heart Failure. Am J Cardiol. 2006 Jun 15;97(12):1759–1764.
   PubMed Web of Science ®Google Scholar
• Felker GM, Ellison DH, Mullens W, et al. Diuretic therapy for patients with heart failure. J Am Coll Cardiol. 2020 Mar;75(10):1178–1195. .
   PubMed Web of Science ®Google Scholar
• Fudim M, Hernandez AF, Felker GM. Role of volume redistribution in the congestion of heart failure. J Am Heart Assoc. 2017 Aug 17;6(8). [[cited 2020 Jul 19]]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586477/
   PubMed Web of Science ®Google Scholar
• Fudim M, Yalamuri S, Herbert JT, et al. Raising the pressure: hemodynamic effects of splanchnic nerve stimulation. J Appl Physiol. 2017 Mar 30;123(1):126–127.
   PubMed Web of Science ®Google Scholar
• Boorsma EM, terMaaten JM, Damman K, et al. Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. Nat Rev Cardiol. 2020;15(May):1–15.
   Google Scholar
• Henri O, Pouehe C, Houssari M, et al. Selective stimulation of cardiac lymphangiogenesis reduces myocardial edema and fibrosis leading to improved cardiac function following myocardial infarction. Circulation. 2016 Apr 12;133(15):1484–1497. discussion 1497.
   PubMed Web of Science ®Google Scholar
• Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol. 2017 Jan;14(1):30–38.
   PubMed Web of Science ®Google Scholar
• Colombo PC, Doran AC, Onat D, et al. Venous congestion, endothelial and neurohormonal activation in acute decompensated heart failure: cause or effect? Curr Heart Fail Rep. 2015 Jun;12(3):215–222. .
   PubMedGoogle Scholar
• Casu G, Merella P. Diuretic therapy in heart failure – current approaches. Eur Cardiol. 2015 Jul;10(1):42–47.
   PubMed Web of Science ®Google Scholar
• Testani JM, Chen J, McCauley BD, et al. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation. 2010 Jul 20;122(3):265–272.
   PubMed Web of Science ®Google Scholar
• AK J, Chen HH. ROSE-AHF and lessons learned. Curr Heart Fail Rep. 2014 Sep;11(3):260–265.
   PubMedGoogle Scholar
• Ahmad T, Jackson K, Rao VS, et al. worsening renal function in patients with acute heart failure undergoing aggressive diuresis is not associated with tubular injury. Circulation. 2018 May 8;137(19):2016–2028. .
   PubMed Web of Science ®Google Scholar
• Francis GS. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Ann Intern Med. 1985;103(1):6. .
   PubMed Web of Science ®Google Scholar
• Mentz RJ, Stevens SR, DeVore AD, et al. Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure. JACC Heart Fail. 2015 Feb;3(2):97–107. .
   PubMed Web of Science ®Google Scholar
• Rahn KH. Clinical pharmacology of diuretics. Ann Clin Exp Hypertens. 1983;A5(2):157–166.
   Google Scholar
• Hammarlund MM, Paalzow LK, Odlind B. Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis. Eur J Clin Pharmacol. 1984 Mar;26(2):197–207.
   PubMed Web of Science ®Google Scholar
• Buggey J, Mentz RJ, Pitt B, et al. A reappraisal of loop diuretic choice in heart failure patients. Am Heart J. 2015 Mar;169(3):323–333. .
   PubMed Web of Science ®Google Scholar
• Abraham B, Megaly M, Sous M, et al. Meta-Analysis comparing torsemide versus furosemide in patients with heart failure. Am J Cardiol. 2020 Jan 1;125(1):92–99. .
   PubMed Web of Science ®Google Scholar
• Kaojarern S, Day B, Brater DC. The time course of delivery of furosemide into urine: an independent determinant of overall response. Kidney Int. 1982;22(1):69–74.
   PubMed Web of Science ®Google Scholar
• Ferguson JA, Sundblad KJ, Becker PK, et al. Role of duration of diuretic effect in preventing sodium retention. Clin Pharmacol Ther. 1997 Aug;62(2):203–208.
   PubMed Web of Science ®Google Scholar
• Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med. 2017;377(20):1964–1975.
   PubMed Web of Science ®Google Scholar
• Ellison DH. Clinical pharmacology in diuretic use. Clin J Am Soc Nephrol. 2019;14(8):1248–1257.
   PubMed Web of Science ®Google Scholar
• Subramanya AR, Ellison DH. Distal convoluted tubule. Clin J Am Soc Nephrol. 2014;9(12):2147–2163.
   PubMed Web of Science ®Google Scholar
• Olesen KH, Sigurd B. The supra-additive natriuretic effect addition of quinethazone or bendroflumethiazide during long-term treatment with furosemide and spironolactone. Acta Medica Scandinavica. 1971;190(1–6):233–240.
   Google Scholar
• Cunningham JW, Sun J, Mc Causland FR, et al. Lower urine sodium predicts longer length of stay in acute heart failure patients: insights from the ROSE AHF trial. Clin Cardiol. 2019 Nov 12;43(1):43–49.
   PubMed Web of Science ®Google Scholar
• Doering A, Jenkins CA, Storrow AB, et al. Markers of diuretic resistance in emergency department patients with acute heart failure. Int J Emerg Med. 2017;10(1):1.
   PubMedGoogle Scholar
• Yamato M, Sasaki T, Honda K, et al., Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ J. 67(5): 384–390. 2003; .
   PubMed Web of Science ®Google Scholar
• Kasama S, Toyama T, Hatori T, et al. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. Heart. 2006 Oct;92(10):1434–1440.
   PubMed Web of Science ®Google Scholar
• Tsutamoto T, Sakai H, Wada A, et al. Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol. 2004 Dec 7;44(11):2252–2253.
   PubMed Web of Science ®Google Scholar
• Stroupe KT, Forthofer MM, Brater DC, et al. Healthcare costs of patients with heart failure treated with torasemide or furosemide. Pharmacoeconomics. 2000 May 1;17(5):429–440.
   PubMed Web of Science ®Google Scholar
• Young M, Plosker GL. Torasemide. Pharmacoeconomics. 2001 Jun 1;19(6):679–703.
   PubMedGoogle Scholar
• Buckley LF, Seoane-Vazquez E, Cheng JWM, et al. Comparison of ambulatory, high-dose, intravenous diuretic therapy to standard hospitalization and diuretic therapy for treatment of acute decompensated heart failure. Am J Cardiol. 2016 Nov 1;118(9):1350–1355.
   PubMed Web of Science ®Google Scholar
• Roberts JD, Gerberich A, Makkar K, et al. Outpatient diuretic infusion clinic: a home for high risk heart failure patients. J Card Fail. 2018Aug1;24(8):S129.
   Web of Science ®Google Scholar
• Buckley LF, Carter DM, Matta L, et al. Intravenous diuretic therapy for the management of heart failure and volume overload in a multidisciplinary outpatient unit. JACC Heart Fail. 2016 Jan 1;4(1):1–8.
   PubMed Web of Science ®Google Scholar
• Open Access to an Outpatient Intravenous Diuresis Program in a Systolic Heart Failure Disease Management Program - Hebert - 2011 - Congestive Heart Failure - Wiley Online Library [Internet]. [cited 2020 May 15]. Available from: https://onlinelibrary-wiley-com.eresources.mssm.edu/doi/full/10.1111/j.1751-7133.2011.00224.x
   Google Scholar
• Jentzer JC, Dewald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol. 2010;56(19):1527–1534. . Elsevier USA
   PubMed Web of Science ®Google Scholar
• Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: A report of the american college of cardiology foundation/american heart association task force on practice guidelines: Developed in collaboration with the international society for heart and lung transplantation. Circulation. 2009;119:20–23.
   Google Scholar
• Carter LM, Beavers JC, Russell SD. The myth of metolazone-does dose timing with loop diuretics matter? J Card Fail. 2019 Aug 1;25(8):S131–2.
   Web of Science ®Google Scholar
• Hoorn EJ, Nelson JH, McCormick JA, et al. The WNK kinase network regulating sodium, potassium, and blood pressure. J Am Soc Nephrol. 2011;22(4):605–614.
   PubMed Web of Science ®Google Scholar
• Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011 Mar 3;364(9):797–805.
   PubMed Web of Science ®Google Scholar
• Grodin JL, Stevens SR, De Las Fuentes L, et al. Intensification of medication therapy for cardiorenal syndrome in acute decompensated heart failure. J Card Fail. 2016;22(1):26–32. .
   PubMed Web of Science ®Google Scholar
• Brisco-Bacik MA, Ter Maaten JM, Houser SR, et al. Outcomes associated with a strategy of adjuvant metolazone or high-dose loop diuretics in acute decompensated heart failure: A propensity analysis. J Am Heart Assoc. 2018 Sep 1;7(18):18.
   Web of Science ®Google Scholar
• Chlorthalidone – a renaissance in use?: Expert Opinion on Pharmacotherapy: Vol 10, No 13 [Internet]. [ cited 2020 Jul 22]. Available from: https://www.tandfonline.com/doi/full/10.1517/14656560903158956
   Google Scholar
• Ernst ME, Carter BL, Zheng S, et al. Meta-analysis of dose–response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. Am J Hypertens. 2010 Apr 1;23(4):440–446.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Sinha AD. Thiazide diuretics in advanced chronic kidney disease. J Am Soc Hypertens. 2012;6(5):299–308.
   PubMed Web of Science ®Google Scholar
• Fliser D, Schröter M, Neubeck M, et al. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int. 1994 Aug 1;46(2):482–488.
   PubMed Web of Science ®Google Scholar
• Weber KT. Aldosterone and spironolactone in heart failure. N Engl J Med. 1999 Sep 2;341(10):753–755.
   PubMed Web of Science ®Google Scholar
• Struthers A, Krum H, Williams GHA. Comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol. 2008;31(4):153–158.
   PubMed Web of Science ®Google Scholar
• Maron BA, Leopold JA. Mineralocorticoid receptor antagonists and endothelial function. Curr Opin Invest Drugs. 2008; 9. Sep(9):963–969.
   Google Scholar
• Sica DA. Aldosterone and volume management in hypertensive heart disease. Vol. 34, Seminars in Nephrology. W.B. Saunders. 2014;323–332.
   Google Scholar
• Milliez P, DeAngelis N, Rucker-Martin C, et al. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J. 2005 Oct 1;26(20):2193–2199.
   PubMed Web of Science ®Google Scholar
• Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol. 2000 Jun;32(6):865–879.
   PubMed Web of Science ®Google Scholar
• Ouvrard-Pascaud A, Sainte-Marie Y, Bénitah J-P, et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening Arrhythmias. Circulation. 2005 Jun 14;111(23):3025–3033.
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999 Sep 2;341(10):709–717. .
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003 Apr 3;348(14):1309–1321.
   PubMed Web of Science ®Google Scholar
• Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011 Jan 6;364(1):11–21.
   PubMed Web of Science ®Google Scholar
• Butler J, Anstrom KJ, Felker GM, et al. Efficacy and safety of spironolactone in acute heart failure: the athena-hf randomized clinical trial. JAMA Cardiol. 2017 Sep 1;2(9):950–958.
   PubMed Web of Science ®Google Scholar
• Sica DA, Flack JM. Treatment considerations with aldosterone receptor antagonists. J Clin Hypertens. 2011 Jan 1;13(1):65–69.
   Web of Science ®Google Scholar
• Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014 Apr 10;370(15):1383–1392. .
   PubMed Web of Science ®Google Scholar
• de Denus S, O’Meara E, Desai AS, et al. Spironolactone Metabolites in TOPCAT — new insights into regional variation. N Engl J Med. 2017 Apr 27;376(17):1690–1692.
   PubMed Web of Science ®Google Scholar
• Verbrugge F H, Dupont M, Bertrand P B, et al. Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload. Acta Cardiol. 2015 Jun;70(3):265–273.
   PubMed Web of Science ®Google Scholar
• Wongboonsin J, Thongprayoon C, Bathini T et al. Acetazolamide therapy in patients with heart failure: a meta-analysis. J Clin Med. 2019;Mar12 [cited 2020 May 23] 8:3 DOI: 10.3390/jcm8030349.
   PubMed Web of Science ®Google Scholar
• Verbrugge FH, Martens P, Ameloot K, et al. Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance. Eur J Heart Fail. 2019;21(11):1415–1422.
   PubMed Web of Science ®Google Scholar
• Imiela T, Budaj A. Acetazolamide as add-on diuretic therapy in exacerbations of chronic heart failure: a pilot study. Clin Drug Investig. 2017;37(12):1175–1181.
   PubMed Web of Science ®Google Scholar
• Mullens W, Verbrugge FH, Nijst P, et al. Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial. Eur J Heart Fail. 2018 Nov 1;20(11):1591–1600.
   PubMed Web of Science ®Google Scholar
• Ansary TM, Nakano D, Nishiyama A. Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System. Int J Mol Sci. [Internet]. 2019 Feb 1;20(3). Available from.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387046/
   Web of Science ®Google Scholar
• Abdul-Ghani MA, DeFronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30–50% of filtered glucose load in humans. Diabetes. 2013 Oct;62(10):3324–3328.
   PubMed Web of Science ®Google Scholar
• Rajeev SP, Cuthbertson DJ, Wilding JPH. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition. Diabetes Obesity Metab. 2016 Feb 1;18(2):125–134.
   PubMed Web of Science ®Google Scholar
• Packer M. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion. Cardiovasc Diabetol. 2019 Oct 4;18(1):129.
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019 Jan;393(10166):31–39.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019 Nov 21;381(21):1995–2008. .
   PubMed Web of Science ®Google Scholar
• Arnott C, Li Q, Kang A, et al. Sodium‐glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis. JAHA [cited 2020 Jul 21]. 2020 Feb 4;9(3). Available from https://www.ahajournals.org/doi/10.1161/JAHA.119.014908
   Google Scholar
• Filippatos TD, Liontos A, Papakitsou I, et al. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. Postgrad Med. 2019 Mar;131(2):82–88.
   PubMed Web of Science ®Google Scholar
• Yuliya L, Petter B, Udell JA, et al. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications and summary of clinical trials. Circulation. 2017 Oct 24;136(17):1643–1658.
   PubMed Web of Science ®Google Scholar
• Sano M, Takei M, Shiraishi Y, et al. Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res. 2016 Dec;8(12):844–847.
   PubMedGoogle Scholar
• Inzucchi SE, Zinman B, Fitchett D, et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME Trial. Diabetes Care. 2018 Feb 1;41(2):356–363.
   PubMed Web of Science ®Google Scholar
• Cherney DZ, Kanbay M, Lovshin JA. Renal physiology of glucose handling and therapeutic implications. Nephrol Dial Transplant. 2020 Jan 1;35(Supplement_1):i3–12.
   PubMedGoogle Scholar
• Chilton R, Tikkanen I, Cannon CP, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obesity Metab. 2015 Dec 1;17(12):1180–1193.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care. 2016Jul1;39(7):1108–1114.
   PubMed Web of Science ®Google Scholar
• Wan N, Rahman A, Hitomi H, et al. The effects of sodium-glucose cotransporter 2 inhibitors on sympathetic nervous activity. Front Endocrinol (Lausanne) . 2018 Jul 26 [cited 2020 May 6];9.DOI: 10.3389/fendo.2018.00421
   Web of Science ®Google Scholar
• Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018 Oct 1;61(10):2108–2117.
   PubMed Web of Science ®Google Scholar
• Schneider MP, Raff U, Kopp C, et al. Skin sodium concentration correlates with left ventricular hypertrophy in CKD. J Am Soc Nephrol. 2017 Jun;28(6):1867–1876.
   PubMed Web of Science ®Google Scholar
• Karg MV, Bosch A, Kannenkeril D, et al. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. Cardiovasc Diabetol. 2018Jan4 cited 2020 May 6;17.1 DOI: 10.1186/s12933-017-0654-z.
   Google Scholar
• Ueda P, Svanström H, Melbye M, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018 Nov 14 [cited 2020 Jul 17];363. Available from: https://www.bmj.com/content/363/bmj.k4365.
   PubMedGoogle Scholar
• Rouleau J-L, Packer M, Moyé L, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol. 1994 Sep 1;24(3):583–591.
   PubMed Web of Science ®Google Scholar
• Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007 Mar 28;297(12):1319–1331. .
   PubMed Web of Science ®Google Scholar
• Pang PS, Konstam MA, Krasa HB, et al. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J. 2009 Sep;30(18):2233–2240. .
   PubMed Web of Science ®Google Scholar
• Hauptman PJ, Burnett J, Gheorghiade M, et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. J Card Fail. 2013 Jun 1;19(6):390–397.
   PubMed Web of Science ®Google Scholar
• Felker GM, Mentz RJ, Cole RT, et al. Efficacy and safety of tolvaptan in patients hospitalized with acute Heart Failure. J Am Coll Cardiol. 2017 Mar 13;69(11):1399–1406.
   PubMed Web of Science ®Google Scholar
• Konstam MA, Kiernan M, Chandler A, et al. Short-term effects of tolvaptan in patients with acute heart failure and volume overload. J Am Coll Cardiol. 2017 Mar 21;69(11):1409–1419.
   PubMed Web of Science ®Google Scholar
• Kinugawa K, Inomata T, Sato N, et al. Effectiveness and adverse events of tolvaptan in octogenarians with heart failureInterim analyses of samsca post-marketing surveillance in heart faiLurE (SMILE study). Int Heart J. 2015;56(2):137–143.
   PubMed Web of Science ®Google Scholar
• Research C for DE and. FDA Drug Safety Communication: FDA limits duration and usage of Samsca (tolvaptan) due to possible liver injury leading to organ transplant or death. FDA [Internet].[ updated 2019 Jun 21]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-limits-duration-and-usage-samsca-tolvaptan-due-possible-liver
   Google Scholar
• Jhund PS, McMurray JJV. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Heart. 2016 Sep 1;102(17):1342–1347.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993–1004. .
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019 Oct 24;381(17):1609–1620.
   PubMed Web of Science ®Google Scholar
• Vardeny O, Claggett B, Kachadourian J, et al. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM‐HF trial. Eur J Heart Fail. 2019 Mar;21(3):337–341.
   PubMed Web of Science ®Google Scholar
• Wang T-D, Tan R-S, Lee H-Y, et al. Effects of sacubitril/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and nt-probnp in salt-sensitive hypertension. Hypertension. 2017 Jan;69(1):32–41. .
   PubMed Web of Science ®Google Scholar
• Morimoto A, Uzu T, Fujii T, et al. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet. 1997 Dec 13;350(9093):1734–1737.
   PubMed Web of Science ®Google Scholar
• Sauer AJ, Cole R, Jensen BC, et al. Practical guidance on the use of sacubitril/valsartan for heart failure. Heart Fail Rev. 2019;24(2):167–176.
   PubMed Web of Science ®Google Scholar
• Adams KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the acute decompensated heart failure national registry (ADHERE). Am Heart J. 2005 Feb 1;149(2):209–216.
   PubMed Web of Science ®Google Scholar
• DA S, Muntendam P, RL M, et al. Subcutaneous furosemide in heart failure. JACC Basic Transl Sci. 2018 Feb 7;3(1):25–34.
   PubMedGoogle Scholar
• Grogono JC, Butler C, Izadi H, et al. Inhaled furosemide for relief of air hunger versus sense of breathing effort: a randomized controlled trial. Respir Res. 2018 Sep 20;19(1):181.
   PubMedGoogle Scholar
• Newton PJ, Davidson PM, Krum H, et al. The acute haemodynamic effect of nebulised frusemide in stable, advanced heart failure. Heart Lung Circ. 2012 May 1;21(5):260–266.
   PubMed Web of Science ®Google Scholar
• Sudo T, Hayashi F, Nishino T. Responses of tracheobronchial receptors to inhaled furosemide in anesthetized rats. Am J Respir Crit Care Med. 2000 Sep 1;162(3):971–975.
   PubMed Web of Science ®Google Scholar
• Stanke F, Devillier P, Bréant D, et al. Frusemide inhibits angiotensin II-induced contraction on human vascular smooth muscle. Br J Clin Pharmacol. 1998 Dec;46(6):571–575.
   PubMed Web of Science ®Google Scholar
• Paterna S, Gaspare P, Fasullo S, et al. Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend? Clin Sci (Lond). 2008 Feb 1;114(3):221–230.
   PubMed Web of Science ®Google Scholar
• Hummel SL, Karmally W, Gillespie BW et al. Home-delivered meals postdischarge from heart failure hospitalization: the gourmet-hf pilot study. Circ Heart Fail. 2018;Aug cited 2020 Oct 26 11:8 Available fromhttps://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.117.004886.
   Web of Science ®Google Scholar
• Doukky R, Avery E, Mangla A, et al. Impact of dietary sodium restriction on heart failure outcomes. JACC Heart Fail. 2016 Jan;4(1):24–35.
   PubMed Web of Science ®Google Scholar
• Paterna S, Parrinello G, Amato P, et al. Tolerability and efficacy of high-dose furosemide and small-volume hypertonic saline solution in refractory congestive heart failure. Adv Ther. 1999 Oct;16(5):219–228.
   PubMed Web of Science ®Google Scholar
• Liszkowski M, Nohria A. Rubbing salt into wounds: hypertonic saline to assist with volume removal in heart failure. Curr Heart Fail Rep. 2010 Sep 1;7(3):134–139.
   PubMedGoogle Scholar
• Mouren S, Delayance S, Mion G, et al. Mechanisms of increased myocardial contractility with hypertonic saline solutions in isolated blood-perfused rabbit hearts. Anesthesia Analg. 1995 Oct;81(4):777–782.
   PubMed Web of Science ®Google Scholar
• Paterna S, Fasullo S, Cannizzaro S, et al. Short-term effects of hypertonic saline solution in acute heart failure and long-term effects of a moderate sodium restriction in patients with compensated heart failure with new york heart association class III (Class C) (SMAC-HF Study). Am J Med Sci. 2011 Jul 1;342(1):27–37.
   PubMed Web of Science ®Google Scholar
• Gandhi S, Mosleh W, Myers RBH. Hypertonic saline with furosemide for the treatment of acute congestive heart failure: A systematic review and meta-analysis. Int J Cardiol. 2014 May 1;173(2):139–145.
   PubMed Web of Science ®Google Scholar
• Griffin M, Soufer A, Goljo E, et al. Real world use of hypertonic saline in refractory acute decompensated heart failure. JACC Heart Fail. 2020 Mar;8(3):199–208.
   PubMed Web of Science ®Google Scholar
• Levin MH, Fuente R, Verkman AS. Urearetics: a small molecule screen yields nanomolar potency inhibitors of urea transporter UT‐B. Faseb J. 2007 Feb 3;21(2):551–563.
   PubMed Web of Science ®Google Scholar
• Klein JD, Sands JM. Urea transport and clinical potential of urearetics. Vol. 25, current opinion in nephrology and hypertension. Lippincott Williams and Wilkins; 2016. p. 444–451.
   Google Scholar
• Bart Bradley A. Treatment of congestion in congestive heart failure: ultrafiltration is the only rational initial treatment of volume overload in decompensated heart failure. Circulation. 2009 Sep 1;2(5):499–504.
   PubMed Web of Science ®Google Scholar
• Bart BA, Boyle A, Bank AJ, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the relief for acutely fluid-overloaded patients with decompensated congestive heart failure (rapid-chf) trial. J Am Coll Cardiol. 2005 Dec 6;46(11):2043–2046.
   PubMed Web of Science ®Google Scholar
• Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007 Feb 13;49(6):675–683. .
   PubMed Web of Science ®Google Scholar
• Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012 Dec 13;367(24):2296–2304.
   PubMed Web of Science ®Google Scholar
• Costanzo MR, Negoianu D, Jaski BE, et al. Aquapheresis versus intravenous diuretics and hospitalizations for heart failure. JACC Heart Fail. 2016 Feb 1;4(2):95–105.
   PubMed Web of Science ®Google Scholar
• Ronco C, Crepaldi C, Rosner MH (editors). Remote Patient Management in Peritoneal Dialysis. In: Contribution of Nephrol. Basel: Karger. 2019, vol 197, pp 54–64. doi:DOI: 10.1159/000496309
   Google Scholar
• Puttagunta H, Holt SG Peritoneal Dialysis for Heart Failure: Peritoneal Dialysis International [Internet].[ updated 2015 Nov 1 cited 2020 May 17]; Available from: http://journals.sagepub.com/doi/10.3747/pdi.2014.00340
   Google Scholar
• Bertoli SV, Musetti C, Ciurlino D, et al. Peritoneal ultrafiltration in refractory heart failure: a cohort study. Perit Dial Int. 2014 Feb;34(1):64–70. .
   PubMed Web of Science ®Google Scholar
• Kunin M, Arad M, Dinour D, et al. Peritoneal dialysis in patients with refractory congestive heart failure: potential prognostic factors. BPU. 2013;35(4):285–294.
   Web of Science ®Google Scholar
• Cnossen TT, Kooman JP, Krepel HP, et al. Prospective study on clinical effects of renal replacement therapy in treatment-resistant congestive heart failure. Nephrol Dial Transplant. 2012 Jul 1;27(7):2794–2799.
   PubMed Web of Science ®Google Scholar
• Núñez J, Teruel A, Quiñones-Torrelo C, et al. Continuous ambulatory peritoneal dialysis as a promising therapy for light chain amyloidosis with congestive heart failure. Int J Cardiol. 2016 Nov;223:807–809.
   PubMed Web of Science ®Google Scholar
• Courivaud C, Kazory A, Crépin T, et al. Peritoneal dialysis reduces the number of hospitalization days in heart failure patients refractory to diuretics. Perit Dial Int. 2014 Feb;34(1):100–108. .
   PubMed Web of Science ®Google Scholar
• Hospital Readmissions Reduction Program (HRRP) | CMS [Internet]. [cited 2020 May 28]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Readmissions-Reduction-Program
   Google Scholar
• Dhruva SS, Krumholz HM. Championing effectiveness before cost-effectiveness. JACC Heart Fail. 2016;4(5):376–379.
   PubMed Web of Science ®Google Scholar
• Boriani G, Da Costa A, Quesada A, et al. Effects of remote monitoring on clinical outcomes and use of healthcare resources in heart failure patients with biventricular defibrillators: results of the MORE-CARE multicentre randomized controlled trial. Eur J Heart Fail. 2017;19(3):416–425.
   PubMed Web of Science ®Google Scholar
• Morgan JM, Kitt S, Gill J, et al. Remote management of heart failure using implantable electronic devices. Eur Heart J. 2017 Aug 7;38(30):2352–2360.
   PubMed Web of Science ®Google Scholar